Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
73 hedge funds and large institutions have $35.1M invested in Orexigen Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 33 reducing their positions, and 40 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less funds holding
Funds holding: 104 → 73 (-31)
37% less capital invested
Capital invested by funds: $55.3M → $35.1M (-$20.2M)
70% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 33
75% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 40
77% less call options, than puts
Call options by funds: $25K | Put options by funds: $109K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.37M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$358K |
| 3 |
Millennium Management
New York
|
+$273K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$83.6K |
| 5 |
Squarepoint
New York
|
+$81.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.17M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.3M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.51M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.49M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.47M |
OREX Hedge Fund Activity: Q2 2016 in Review
73 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q2 2016, worth a combined $35.1M — down 37% from $55.3M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of OREX and 10 opened new positions — a net loss of 30 holders — while 33 trimmed existing stakes and 10 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $2.37M. The largest seller was Fidelity Investments, exiting entirely with an estimated $4.17M sold.
- 73 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q2 2016, down from 104 in Q1 2016.
- Funds reported $35.1M of Orexigen Therapeutics, Inc. stock for Q2 2016, down 37% quarter-over-quarter.
- 10 funds opened new Orexigen Therapeutics, Inc. positions in Q2 2016 and 40 closed out, a net change of -30 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q2 2016 was BVF Inc, an estimated $2.37M added.
- The largest Orexigen Therapeutics, Inc. seller in Q2 2016 was Fidelity Investments, an estimated $4.17M sold.
Based on aggregated 13F filings for Q2 2016.